POC Glucose Monitoring Devices Market to Reach USD 2 Billion in 2022
By LabMedica International staff writers Posted on 04 Apr 2018 |
The global POC blood glucose monitoring devices market is expected to reach USD 2.03 billion in 2022, driven mainly by public and private initiatives to reduce diabetic cases. However, the high cost associated with diabetes management is one of the major factors hindering the market growth.
These are the latest findings of Research and Markets, (Dublin, Ireland), a global market research company.
Most POC blood glucose monitoring devices manufactured by global and local players are cost-efficient. However, the cost associated with diabetes management in high, resulting in out-of-pocket expenditure for consumables used in POC blood glucose monitoring devices. These consumables, including blood glucose test strips, reagents, and cassettes are expensive and are required on a daily basis. Moreover, an invasive device such as lancet needs to be purchased separately along with the POC blood monitoring devices, resulting in additional cost being incurred.
Of late, there has been a paradigm shift to non-invasive products in the POC blood glucose monitoring devices market. Non-invasive POC blood glucose monitoring devices are hand-held units that offer a number of benefits over finger prick glucose test, such as helping to avoid finger prick and providing a convenient, easy to read large number display. Non-invasive POC blood glucose monitoring devices can also track patient compliance and allow multiple tests to be run in order to allow healthcare providers to provide adequate therapeutic decisions.
Related Links:
Research and Markets
These are the latest findings of Research and Markets, (Dublin, Ireland), a global market research company.
Most POC blood glucose monitoring devices manufactured by global and local players are cost-efficient. However, the cost associated with diabetes management in high, resulting in out-of-pocket expenditure for consumables used in POC blood glucose monitoring devices. These consumables, including blood glucose test strips, reagents, and cassettes are expensive and are required on a daily basis. Moreover, an invasive device such as lancet needs to be purchased separately along with the POC blood monitoring devices, resulting in additional cost being incurred.
Of late, there has been a paradigm shift to non-invasive products in the POC blood glucose monitoring devices market. Non-invasive POC blood glucose monitoring devices are hand-held units that offer a number of benefits over finger prick glucose test, such as helping to avoid finger prick and providing a convenient, easy to read large number display. Non-invasive POC blood glucose monitoring devices can also track patient compliance and allow multiple tests to be run in order to allow healthcare providers to provide adequate therapeutic decisions.
Related Links:
Research and Markets
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus